Retinal and Choroidal Changes in Patients with Systemic Arterial Hypertension
Published: 2022-09-27
Page: 72-80
Issue: 2022 - Volume 5 [Issue 1]
Samar R. El-Mawy *
Tanta Ophthalmology Hospital, Ministry of Health, Elgharbia Province, Egypt.
Mona S. El-Koddousy
Department of Ophthalmology, Tanta University, Tanta, Elgharbia Province, Egypt.
Mustafa A. Abo-Elenin
Department of Ophthalmology, Tanta University, Tanta, Elgharbia Province, Egypt.
Elsaied I. El-Desouky
Department of Ophthalmology, Tanta University, Tanta, Elgharbia Province, Egypt.
*Author to whom correspondence should be addressed.
Abstract
Aims: To evaluate retinal and choroidal changes in patients with systemic arterial hypertension using optical coherence tomography (OCT).
Setting: The study was performed in the outpatient clinic of Tanta ophthalmology Hospital.
Design: Prospective, cross sectional and controlled study.
Patients and Methods: Retinal and choroidal changes using spectral domain optical coherence tomography that includes the following parameters: central macular thickness (CMT), Subfoveal choroidal thickness (SFCT), and Retinal nerve fiber layer thickness (RNFL).
Results: The study comprised 10 eyes of healthy individuals without hypertension, 15 eyes of systemic hypertensive patients on beta blockers for more than one year, and 15 eyes of systemic hypertensive patients on calcium channel blockers for more than one year. This study showed There were statistically significant differences between the three studied groups as regards the mean central macular thickness (CMT). In this study, we found a statistically significant decrease in the mean subfoveal choroidal thickness (SFCT) from 247.40 ± 46.18 µm in group A (non hypertensive) to 195.63 ± 28.96 µm in group B (hypertensive patients on beta blockers for more than one year) and decreased to 203.10 ± 27.74 µm in group C (hypertensive patients on calcium channel blockers for more than one year). According to the retinal nerve fiber layer thickness (RNFL), our study showed (100%) were within normal thickness in group A (non-hypertensive), In group B (hypertensive patients on beta blockers for more than one year) Twelve eyes (40.0%) were within normal thickness, ten eyes (33.3%) had thinning inferior, and eight eyes (26.7%) had thinning superior. Eight eyes (26.7%) were within normal thickness, ten eyes (33.3%) had thinning inferior, four eyes (13.3%) had thinning superior, and eight eyes (26.7%) were borderline in group C (hypertensive patients on calcium channel blockers for more than one year).
Conclusion: Hypertension (HTN) has significant increase in the central macular thickness , lower SFCT and thinning in retinal nerve fiber layer thickness in all quadrants compared to normotensive individuals. Neither beta blockers nor calcium channels blockers have significant changes on these previous parameters changes.
Keywords: Hypertension, central macular thickness, subfoveal choroidal thickness, retinal nerve fiber layer thickness, spectral domain OCT with EDI
How to Cite
References
Chatterjee S, Chattopadhyay S, Hope-Ross M, Lip PL. Hypertension and the eye: changing perspectives. J Hum Hypertens. 2002;16(10):667-75.
Pontremoli R, Sofia A, Tirotta A, Ravera M, Nicolella C, Viazzi F, et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol. 1996; 7(12):2550-8.
Poulter NR. Independent effects of smoking on risk of hypertension: small, if present. J Hypertens. 2002;20(2):171-2.
Wolffsohn JS, Hurcomb PG. Hypertension and the eye. Curr Hypertens Rep. 2002; 4(6):471-6.
Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology. 1982;89(10):1132-45.
Frank RN. The eye in hypertension. In: Izzo JL, Black HR (eds). Hypertension Primer. Dallas, TX: Lippincott Williams& Wilkins. 2003;209-11.
Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010; 55(3):590-8.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11-9.
Henderson AD, Bruce BB, Newman NJ, Biousse V. Hypertension-related eye abnormalities and the risk of stroke. Rev Neurol Dis. 2011;8(1-2):1-9.
Bruce A, Pacey IE, Dharni P, Scally AJ, Barrett BT. Repeatability and reproducibility of macular thickness measurements using fourier domain optical coherence tomography. Open Ophthalmol J. 2009;3:10-4.
Konstantinidis L, Guex-Crosier Y. Hypertension and the eye. Curr Opin Ophthalmol. 2016;27(6):514-21.
Lee HM, Lee WH, Kim KN, Jo YJ, Kim JY. Changes in thickness of central macula and retinal nerve fibre layer in severe hypertensive retinopathy: a 1-year longitudinal study. Acta Ophthalmol. 2018; 96(3):e386-e92.
Masís M, Hernandez E, Wu L. Choroidal thickness in patients with systemic hypertension. Invest Ophthalmol Vis Sci. 2011;52(14):5296.
Akay F, Gundogan FC, Yolcu U, Toyran S, Uzun S. Choroidal thickness in systemic arterial hypertension. Eur J Ophthalmol. 2016;26(2):152-7.
Gök M, Karabas VL, Emre E, Aksar AT, Aslan MS, Ural D. Evaluation of choroidal thickness via enhanced depth-imaging optical coherence tomography in patients with systemic hypertension. Indian J Ophthalmol. 2015;63(3):239-43.
Parver LM. Temperature modulating action of choroidal blood flow. Eye (Lond). 1991;5(Pt 2):181-5.
Nickla DL, Wallman J. The multifunctional choroid. Prog Retin Eye Res. 2010; 29(2):144-68.
Lee SH, Lee WH, Lim HB, Jo YJ, Kim JY. Thicknesses of central macular, retinal nerve fiber, and ganglion cell inner plexiform layers in patients with hypertension. Retina. 2019;39(9):1810- 8.
Lee MW, Lee WH, Park GS, Lim HB, Kim JY. Longitudinal changes in the peripapillary retinal nerve fiber layer thickness in hypertension: 4-Year prospective observational study. Invest Ophthalmol Vis Sci. 2019;60(12):3914-9.